Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early access telaprevir with peginterferon alfa and ribavirin in genotype 1 chronic hepatitis C with severe fibrosis or compensated cirrhosis
2010-023669-23Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telaprevir in hepatitis C virus infection, sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability and Formal statistical hypothesis testing. Started Mar 2011; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-023669-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023669-23.